BioPharma Terug naar discussie overzicht

Intercept Pharma

1. [verwijderd] 10 januari 2014 06:43

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   finance.yahoo.com/q?s=icpt
   
   De biopharma klepper van 2014 tot hiertoe.
2. DeZwarteRidder 30 juni 2020 12:42

   auteur info

   • DeZwarteRidder

     Lid sinds: 29 jun 2012

     Laatste bezoek: 22 mrt 2025

   • Aanbevelingen

     Ontvangen: 24687

     Gegeven: 10676

   •    Aantal posts: 102.627

   Intercept Shares Tumble on NASH Disappointment
   
   By Josh Nathan-Kazis
   June 29, 2020 4:05 pm ET
   
   NASH was once the next big thing for big pharma; a newly defined disorder requiring chronic treatment afflicting millions of people in developed countries. Scores of companies are developing drugs for the disease, which can cause deadly conditions like decompensated cirrhosis or liver cancer.
   
   But the quest for the first big NASH drug has hit some stumbling blocks. In May, a French company called Genfit (ticker: GNFT), which had one of the most advanced NASH programs, announced that a Phase 3 trial of its NASH drug Elafinbranor had failed to achieve its primary endpoint.
   
   Now, another setback is tanking shares of Intercept Pharmaceuticals (ICPT), which analysts had expected to introduce the first NASH drug sometime this year. Intercept had submitted an application for accelerated approval with the Food and Drug Administration for its drug obeticholic acid as a treatment for NASH. On Monday, the company said that the FDA had sent it a letter saying that the expected benefit of the drug “does not sufficiently outweigh the potential risks.”
   
   The company said that the agency had asked for additional analyses from an ongoing study. Shares of Intercept fell 39% on Monday. On an investor call Monday morning, Intercept CEO Mark Pruzanski called the FDA’s action “completely unexpected and disappointing.”
   
   “At no point during review did the FDA communicate that OCA was not approvable on an accelerated basis,” Pruzanski said.
   
   Questions about NASH drugs have been emerging for months. In December, Barron’s highlighted those concerns, arguing that investors should be skeptical of the field.
   
   Intercept’s application for OCA was based on interim data from a study that found that liver scarring improved, and other NASH parameters did not worsen, in 23.1% of patients who received a higher dose of the drug, compared with 11.9% of patients in the placebo arm of the study.
   
   In an interview in December, Pruzanski told Barron’s that the most important metric was the stabilization of fibrosis, and that 40% of the patients in the high dose group improved by a full stage of fibrosis.
   
   The drug also raises levels of so-called bad cholesterol, which could be a concern given that the patients likely to take the drug to treat NASH are also prone to heart disease. In the December interview, an Intercept executive told Barron’s that the risk could be managed with other dugs.
   
   Shares of Intercept are down 61.8% so far this year.